A synthetic pentadecapeptide derived from human gastric juice, studied for its regenerative and protective properties.
Oxidative medicine and cellular longevity|2019|Konosic S et al.
We suggest that the stable gastric pentadecapeptide BPC 157 may rescue thrombocyte function. We focused on the antithrombotic agent aspirin, clopidogrel, and cilostazol application in rats; arachidonic acid, ADP, collagen, and arachidonic acid/PGE1 p…
Animal Study
PMID: 31976029
European journal of pharmacology|2019|Sucic M et al.
We focused on the cyclophosphamide-induced hemorrhagic cystitis (100 mg/kg/day intraperitoneally throughout three days) as a particular NO-system disturbance, and therapy possibilities. We demonstrated that it may be attenuated by subsequent administ…
Animal Study
PMID: 31401154
Journal of orthopaedic surgery and research|2019|Perovic D et al.
BACKGROUND: We focused on the therapeutic effects of the stable gastric pentadecapeptide BPC 157 in spinal cord injury using a rat model. BPC 157, of which the LD1 has not been achieved, has been implemented as an anti-ulcer peptide in inflammatory b…
Animal Study
PMID: 31266512
Cell and tissue research|2019|Gwyer D, Wragg N, Wilson S
There is a current need for a therapy that can alleviate the social and economic burden that presents itself with debilitating and recurring musculoskeletal soft tissue injuries and disorders. Currently, several therapies are emerging and undergoing…
ReviewAnimal Study
PMID: 30915550
World journal of gastroenterology|2018|Amic F et al.
AIM: To investigate whether duodenal lesions induced by major venous occlusions can be attenuated by BPC 157 regardless nitric oxide (NO) system involvement. METHODS: Male Wistar rats underwent superior anterior pancreaticoduodenal vein (SAPDV)-ligat…
Animal Study
PMID: 30598581
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society|2018|Becejac T et al.
With intra(per)-oral strong alcohol application at the tongue, swallowed, we renewed Robert's stomach cytoprotection/adaptive cytoprotection concept. We assessed strong (96%) alcohol-induced severe or minute lesions in stomach, tongue-esophagus-stoma…
Animal Study
PMID: 30279308
Applied microbiology and biotechnology|2018|Škrlec K et al.
Lactic acid bacteria (LAB) are attractive hosts for the expression of heterologous proteins and can be engineered to deliver therapeutic proteins or peptides to mucosal surfaces. The gastric stable pentadecapeptide BPC-157 is able to prevent and trea…
PMID: 30191288
Current pharmaceutical design|2018|Seiwerth S et al.
Commonly, the angiogenic growth factors signify healing. However, gastrointestinal ulceration is still poorly understood particularly with respect to a general pharmacological/pathophysiological role of various angiogenic growth factors implemented i…
ReviewAnimal StudyIn Vitro
PMID: 29998800
Vascular pharmacology|2018|Vukojević J et al.
UNLABELLED: Rat inferior caval vein (ICV) ligation (up to the right ovarian vein (ROV)) commonly represents a recapitulation of Virchow: with ligation leading to vessel injury, stasis, thrombosis and hemodynamic changes. We revealed that BPC 157's th…
Animal Study
PMID: 29510201
Journal of veterinary pharmacology and therapeutics|2018|Tlak Gajger I et al.
Nosema ceranae can cause major problems, such as immune suppression, gut epithelial cell degeneration, reduced honeybee lifespan, or suddenly colony collapse. As a novel approach in therapy, we hypothesize the stable gastric pentadecapeptide BPC 157…
PMID: 29682749
Current pharmaceutical design|2018|Sikiric P et al.
Years ago, we revealed a novel cytoprotective mediator, stable gastric pentadecapeptide BPC 157, particular anti-ulcer peptide that heals different organs lesions when given as a therapy, native in human gastric juice while maintaining GI-tract mucos…
Review
PMID: 29879879
Current pharmaceutical design|2018|Kang E et al.
Cancer cachexia, one of the metabolic syndromes caused by cancer, is a devastating and miserable condition encountered in more than 50% of terminal cancer patients presenting with significant weight loss associated with skeletal muscle atrophy and fa…
Review
PMID: 29898649
World journal of gastroenterology|2018|Drmic D et al.
AIM: To study the counteraction of perforated cecum lesion using BPC 157 and nitric oxide (NO) system agents. METHODS: Alongside with the agents' application (after 1 min, medication (/kg, 10 mL/2 min bath/rat) includes: BPC 157 (10 μg), L-NAME (5 mg…
Animal Study
PMID: 30622376
World journal of gastroenterology|2017|Drmic D et al.
AIM: To counteract/reveal celecoxib-induced toxicity and NO system involvement. METHODS: Celecoxib (1 g/kg b.w. ip) was combined with therapy with stable gastric pentadecapeptide BPC 157 (known to inhibit these lesions, 10 μg/kg, 10 ng/kg, or 1 ng/kg…
Animal Study
PMID: 28839430
Journal of molecular medicine (Berlin, Germany)|2017|Hsieh M et al.
UNLABELLED: BPC 157, a pentadecapeptide with extensive healing effects, has recently been suggested to contribute to angiogenesis. However, the underlying mechanism is not yet clear. The present study aimed to explore the potential therapeutic effect…
Animal StudyIn Vitro
PMID: 27847966
Inflammopharmacology|2017|Medvidovic-Grubisic M et al.
AIM: Stable gastric pentadecapeptide BPC 157, administered before a high-dose magnesium injection in rats, might be a useful peptide therapy against magnesium toxicity and the magnesium-induced effect on cell depolarization. Moreover, this might be a…
Animal StudyIn Vitro
PMID: 28210905
Current pharmaceutical design|2017|Sikiric P et al.
Selye's syndrome produced by diverse nocuous agents and "response to damage as such" means Selye's stress triad in stress coping response to reestablish homeostasis. Logically, from the gastrointestinal tract viewpoint, such organoprotective/healing…
Review
PMID: 28228068
Inflammopharmacology|2017|Luetic K et al.
We revealed a new point with cyclophosphamide (150 mg/kg/day intraperitoneally for 7 days): we counteracted both rat stomach and duodenal ulcers and increased NO- and MDA-levels in these tissues. As a NO-system effect, BPC 157 therapy (10 µg/kg, 10 n…
Animal Study
PMID: 28255738
Inflammopharmacology|2017|Belosic Halle Z et al.
The ulcerogenic potential of dopamine antagonists and L-NAME in rats provides unresolved issues of anti-emetic neuroleptic application in both patients and experimental studies. Therefore, in a 1-week study, we examined the pressures within the lower…
Animal Study
PMID: 28516373
Journal of physiology and pharmacology : an official journal of the Polish Physiological Society|2017|Vitaic S et al.
The sphincters failure is a part of NSAIDs-toxicity that can be accordingly counteracted. We used a safe stable gastric pentadecapeptide BPC 157 (GEPPPGKPADDAGLV, MW 1419), LD1 not achieved, since successful in inflammatory bowel disease trials, and…
Animal Study
PMID: 28614776